Massive Bio, a leading artificial intelligence (AI) analytics company specializing in precision oncology, has been selected by the Precision Cancer Consortium (PCC) to optimize clinical trial matching through their innovative AI analytics tools. PCC is a collaborative initiative to make data-driven precision oncology the new normal for all cancer patients globally, focusing on increasing patient access to targeted Next Generation Sequencing (NGS) testing and tailored interventions. This partnership will incorporate PCC member clinical trial protocols and patient inclusion and exclusion criteria into existing machine learning matching algorithms in SYNERGY-AI leveraged within Massive Bio’s Deep Learning Clinical Trial Matching System (DLCTMS). This will optimize the quality and efficiency of matching patients to trials across sponsor programs and improve patient access to targeted NGS testing and tailored interventions.
Add to Favourites
To login click here